JP2018505666A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505666A5 JP2018505666A5 JP2017534355A JP2017534355A JP2018505666A5 JP 2018505666 A5 JP2018505666 A5 JP 2018505666A5 JP 2017534355 A JP2017534355 A JP 2017534355A JP 2017534355 A JP2017534355 A JP 2017534355A JP 2018505666 A5 JP2018505666 A5 JP 2018505666A5
- Authority
- JP
- Japan
- Prior art keywords
- sfb
- strain
- genetically modified
- culture
- eukaryotic host
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 239000001963 growth medium Substances 0.000 claims 6
- 230000002163 immunogen Effects 0.000 claims 6
- 244000005700 microbiome Species 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 238000012136 culture method Methods 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 229910052742 iron Inorganic materials 0.000 claims 4
- 238000009630 liquid culture Methods 0.000 claims 4
- 230000001580 bacterial effect Effects 0.000 claims 3
- 238000003501 co-culture Methods 0.000 claims 3
- 241000588724 Escherichia coli Species 0.000 claims 2
- 230000021615 conjugation Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 239000012533 medium component Substances 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 230000026683 transduction Effects 0.000 claims 2
- 238000010361 transduction Methods 0.000 claims 2
- 230000009466 transformation Effects 0.000 claims 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims 1
- 101710167241 Intimin Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000001888 Peptone Substances 0.000 claims 1
- 108010080698 Peptones Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 108700009667 Shigella ipaB Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 239000005018 casein Substances 0.000 claims 1
- -1 casein amino acid Chemical class 0.000 claims 1
- 235000021240 caseins Nutrition 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000001332 colony forming effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000369 enteropathogenic effect Effects 0.000 claims 1
- 239000000147 enterotoxin Substances 0.000 claims 1
- 235000020776 essential amino acid Nutrition 0.000 claims 1
- 239000003797 essential amino acid Substances 0.000 claims 1
- 210000000416 exudates and transudate Anatomy 0.000 claims 1
- 239000012091 fetal bovine serum Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 235000019319 peptone Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 239000003104 tissue culture media Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB2014/067285 | 2014-12-23 | ||
| PCT/IB2014/067285 WO2016103005A1 (en) | 2014-12-23 | 2014-12-23 | Method of culturing segmented filamentous bacteria in vitro |
| PCT/IB2015/059948 WO2016103217A1 (en) | 2014-12-23 | 2015-12-23 | Method of culturing segmented filamentous bacteria in vitro |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505666A JP2018505666A (ja) | 2018-03-01 |
| JP2018505666A5 true JP2018505666A5 (cg-RX-API-DMAC7.html) | 2018-09-20 |
| JP6963999B2 JP6963999B2 (ja) | 2021-11-10 |
Family
ID=52462962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534355A Active JP6963999B2 (ja) | 2014-12-23 | 2015-12-23 | セグメント細菌のインビトロ培養法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10435665B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3237602B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6963999B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107429222B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015370419B2 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2016103005A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016103005A1 (en) * | 2014-12-23 | 2016-06-30 | Institut Pasteur | Method of culturing segmented filamentous bacteria in vitro |
| CN106011281B (zh) * | 2016-07-19 | 2019-04-23 | 浙江大学 | 肠道分节丝状菌鞭毛蛋白的检测方法 |
| DE102018213030A1 (de) * | 2018-08-03 | 2020-02-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien |
| WO2021155229A1 (en) * | 2020-01-31 | 2021-08-05 | Iowa State University Research Foundation, Inc. | Gut bacterium-based treatment to increase poultry gut health and food safety |
| CA3218163A1 (en) | 2021-05-17 | 2022-11-24 | Anne PALERMO | Food product comprising a co-culture of bacteria and fungi |
| WO2026011048A1 (en) * | 2024-07-03 | 2026-01-08 | Ohio State Innovation Foundation | Commensal bacterial antigen as a therapeutic agent for cancers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120276149A1 (en) * | 2009-10-15 | 2012-11-01 | Dan Littman | Methods for modulating bacterial infection |
| EP2556835B1 (en) * | 2010-02-10 | 2015-08-05 | Japan Eco-Science Co. Ltd. | Mixture, dissolving solution and pharmaceutical agent each comprising thermophilic microorganism |
| MX369877B (es) | 2013-02-04 | 2019-11-25 | Seres Therapeutics Inc | Composiciones y metodos. |
| WO2016103005A1 (en) * | 2014-12-23 | 2016-06-30 | Institut Pasteur | Method of culturing segmented filamentous bacteria in vitro |
-
2014
- 2014-12-23 WO PCT/IB2014/067285 patent/WO2016103005A1/en not_active Ceased
-
2015
- 2015-12-23 US US15/538,184 patent/US10435665B2/en active Active
- 2015-12-23 CN CN201580072958.4A patent/CN107429222B/zh active Active
- 2015-12-23 AU AU2015370419A patent/AU2015370419B2/en active Active
- 2015-12-23 EP EP15830866.8A patent/EP3237602B1/en active Active
- 2015-12-23 JP JP2017534355A patent/JP6963999B2/ja active Active
- 2015-12-23 WO PCT/IB2015/059948 patent/WO2016103217A1/en not_active Ceased
-
2019
- 2019-08-22 US US16/548,280 patent/US11725183B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bahey-El-Din | Lactococcus lactis-based vaccines from laboratory bench to human use: an overview | |
| CN104894021B (zh) | 一种副干酪乳杆菌及其应用 | |
| WO2018117263A9 (en) | Compositions and methods for the induction of cd8+ t-cells | |
| JP2012526755A (ja) | 経管栄養法のためのプロバイオティクス含有モジュール | |
| TW202003834A (zh) | 用於誘導cd8+t細胞的組成物及方法 | |
| JP4942831B2 (ja) | 抗アレルギー用組成物 | |
| Del Carmen et al. | Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model | |
| CA2915673C (en) | Immunotherapy composition and use thereof | |
| CN107810264A (zh) | 适于保护微生物的组合物 | |
| ES2407150T3 (es) | Bacteria ácido láctica novedosa con actividad anti-alérgica, agente anti-alérgico, alimento y composición farmacéutica que comprenden, cada uno de ellos, la bacteria ácido láctica, y proceso para la producción del agente anti-alérgico | |
| US20250213673A1 (en) | Compositions and methods | |
| CN108348559A (zh) | 用于生产共轭亚油酸的副干酪乳杆菌、含有其的营养制剂和药物制剂及其用途 | |
| US20190175670A1 (en) | Postbiotic-based composition for treatment of ocular inflammation | |
| CN108779433A (zh) | 属于开菲尔乳杆菌种的细菌菌株在用于产生和/或维持体内稳态状态的儿科学中的应用 | |
| US20130224167A1 (en) | Non-replicating probiotic bacteria and prevention or treatment of infections to reduce absence from school or daycare | |
| Patil et al. | Engineered bacteria: general overview as therapeutic agent and a novel drug delivery system | |
| CA3090043A1 (en) | Postbiotic-based composition for the modulation of immune system activation and protection of mucosal barriers | |
| JP5740613B2 (ja) | 疾患の予防改善剤、持久力向上剤、抗疲労剤、並びにそれらを用いた医薬品および飲食品 | |
| Shin et al. | Assessment of cell adhesion, cell surface hydrophobicity, autoaggregation, and lipopolysaccharide-binding properties of live and heat-killed Lactobacillus acidophilus CBT LA1 | |
| Yamamoto et al. | Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model | |
| KR102305076B1 (ko) | 용암해수 유래 천연 미네랄 코팅 프로바이오틱스의 제조방법 및 이를 이용한 용암해수 유래 천연 미네랄 코팅 프로바이오틱스 분무건조 제제 | |
| CN102732442A (zh) | 一种不含抗性标记的猪霍乱沙门氏菌双基因缺失菌及其应用 | |
| Chassard et al. | Probiotics and health claims: challenges for tailoring their efficacy. | |
| Podder et al. | Efficacy of bacteria in cancer immunotherapy: special emphasis on the potential of mycobacterial species | |
| Salvador-Mira et al. | Erythrocyte-targeted recombinant subunit vaccine: A novel approach to improve viral vaccines in fish |